HCI2509 at 2 μM for 48 h increased TUNEL staining in A673 cells relative to vehicle, consistent with apoptosis-associated DNA fragmentation. This cellular phenotype does not establish a target-specific mechanism. [3]
Recombinant LSD1 inhibition in an HTRF assay
Biochemical assay · Human recombinant LSD1; biotinylated monomethyl H3(1–21)K4 substrate [1]
SP-2509 inhibited LSD1 with a micromolar IC50 in this assay. The figure reports 2.48 ± 1.21 μM; the Results text rounds this to 2.5 μM. This is an assay endpoint, not a treatment dose.
Literature-Reported Treatment Conditions
- Treatment concentration
- Serial compound dilutions; study capped SP-2509 testing at 30 μM because of solubility concerns
- Exposure duration
- 15 min preincubation on ice; 1 h enzyme reaction at 25 °C; 1 h detection at 25 °C
- Method
- HTRF readout; 0.45 nM recombinant LSD1; substrate at Km; 10 μM FAD
- Vehicle
- 0.5% DMSO
- Reported limits
- Exact serial dilution range is not specified in the HTRF subsection.
Methods and source locations
Compound reported in the paper: SP-2509 (HCI2509); Compound label in the paper: SP-2509
Evidence applies to the named research compound and stated model, without salt conversion or supplier-lot equivalence.
Figure 2A,C (SP-2509 row) and caption; Catalytic Inhibitory Potency and Selectivity; Methods: LSD1 HTRF Assay
Inhibition of recombinant LSD1 catalytic activity: Figure 2 reports mean ± SD; N = 2, n = 2 or 3. HTRF methods specify triplicate compound dilutions. Nonlinear four-parameter fit; no-inhibitor activity control and no-enzyme background; highest-dose detection-interference check. — Figure 2A,C (SP-2509 row) and caption; Catalytic Inhibitory Potency and Selectivity; Methods: LSD1 HTRF Assay
LSD1 target engagement in MV(4;11) cells
Cell-based study · Human MV(4;11) acute myeloid leukemia cells [1]
The authors detected no LSD1 target engagement for SP-2509 under the tested conditions. Active comparator inhibitors, including reversible pulrodemstat, produced detectable engagement.
Literature-Reported Treatment Conditions
- Treatment concentration
- 2000, 200, 20 and 2 nM
- Exposure duration
- 24 h
- Method
- Biotinylated LSD1 chemoprobe followed by free/total LSD1 luminescent ELISAs
- Vehicle
- Vehicle control; composition not specified in the target-engagement subsection
- Reported limits
- No exact target-engagement percentages are transcribed from bars.
Methods and source locations
Compound reported in the paper: SP-2509 (HCI2509); Compound label in the paper: SP-2509
Evidence applies to the named research compound and stated model, without salt conversion or supplier-lot equivalence.
Figure 3B and caption; Results paragraph beginning To assess whether the impact on AML cell viability; Methods: Analysis of LSD1 Target Engagement; Discussion
LSD1 target engagement relative to vehicle: Figure 3B: N = 1, n = 3; mean ± SD; vehicle and active inhibitor comparators. Native extracts assayed with a covalent biotinylated probe. — Figure 3B and caption; Results paragraph beginning To assess whether the impact on AML cell viability; Methods: Analysis of LSD1 Target Engagement; Discussion
SP-2509 effects on mitochondrial protein stability
Cell-based study · Human A673 Ewing sarcoma cells [2]
SP-2509 reduced the thermal stability of UQCRFS1, LYRM7 and NDUFS1. UQCRFS1 destabilization was concentration dependent. Total UQCRFS1 and NDUFS1 were depleted at 24–48 h, whereas the heme-containing comparator CYC1 was not similarly depleted.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μM for thermal-shift and total-protein experiments; 2–30,000 nM in the isothermal concentration series
- Exposure duration
- 3 h for CETSA; 3, 24 and 48 h for total-protein immunoblots
- Method
- CETSA Western blot and tubulin-normalized total-protein immunoblot; isothermal CETSA at 48 °C
- Vehicle
- 0.1% DMSO
- Reported limits
- Replication count for the Figure 2 immunoblots is not specified in its caption; exact stability shifts are not inferred.
Methods and source locations
Compound reported in the paper: SP-2509 (HCI2509); Compound label in the paper: SP-2509
Evidence applies to the named research compound and stated model, without salt conversion or supplier-lot equivalence.
Figure 2A,B,E,F and caption; Results: SP-2577/2509 Alters the Stability; SP-2509 Destabilizes UQCRFS1; SP-2509 Causes a Time-Dependent Depletion; Reagents; CETSA/isothermal CETSA/Western Blot methods
Thermal stability and abundance of mitochondrial proteins: Figure 2A,B,E,F viewed; tubulin normalization and CYC1 comparator. No exact band intensity is inferred. — Figure 2A,B,E,F and caption; Results: SP-2577/2509 Alters the Stability; SP-2509 Destabilizes UQCRFS1; SP-2509 Causes a Time-Dependent Depletion; Reagents; CETSA/isothermal CETSA/Western Blot methods
Apoptosis-associated DNA fragmentation in A673 cells
Cell-based study · Human A673 Ewing sarcoma cells [3]
HCI2509 increased TUNEL staining relative to vehicle in A673 cells, supporting apoptosis-associated DNA fragmentation under these conditions.
Literature-Reported Treatment Conditions
- Treatment concentration
- 2 μM
- Exposure duration
- 48 h
- Method
- DeadEnd Colorimetric TUNEL assay
- Vehicle
- 0.3% DMSO
- Reported limits
- The TUNEL panel is qualitative; no percentage of positive cells or replicate count is specified in its caption.
Methods and source locations
Compound reported in the paper: SP-2509 (HCI2509); Compound label in the paper: HCI2509
Evidence applies to the named research compound and stated model, without salt conversion or supplier-lot equivalence.
Figure 3D,E and caption; Methods: In vitro apoptosis assays; Results paragraph discussing TUNEL staining and caspase activation
TUNEL-positive staining: Figure 3D viewed; negative control lacks labeling, positive control is DNase treatment with labeling. — Figure 3D,E and caption; Methods: In vitro apoptosis assays; Results paragraph discussing TUNEL staining and caspase activation